JP2017505285A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017505285A5 JP2017505285A5 JP2016532631A JP2016532631A JP2017505285A5 JP 2017505285 A5 JP2017505285 A5 JP 2017505285A5 JP 2016532631 A JP2016532631 A JP 2016532631A JP 2016532631 A JP2016532631 A JP 2016532631A JP 2017505285 A5 JP2017505285 A5 JP 2017505285A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- agent according
- salt
- compound
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 claims 13
- 229940124597 therapeutic agent Drugs 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- JWHYSEDOYMYMNM-QGZVFWFLSA-N 2-[4-[(2r)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]sulfanyl-2-methylphenoxy]acetic acid Chemical group C([C@@H](OCC)CSC=1C=C(C)C(OCC(O)=O)=CC=1)OC1=CC=C(C(F)(F)F)C=C1 JWHYSEDOYMYMNM-QGZVFWFLSA-N 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 229940122392 PCSK9 inhibitor Drugs 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- SBZKOWAPPRXYGA-XRIGFGBMSA-N (2s)-2,6-diaminohexanoic acid;dihydrate Chemical compound O.O.NCCCC[C@H](N)C(O)=O SBZKOWAPPRXYGA-XRIGFGBMSA-N 0.000 claims 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims 1
- 229960002027 evolocumab Drugs 0.000 claims 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 claims 1
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361906837P | 2013-11-20 | 2013-11-20 | |
US61/906,837 | 2013-11-20 | ||
US201461942438P | 2014-02-20 | 2014-02-20 | |
US61/942,438 | 2014-02-20 | ||
US201461942941P | 2014-02-21 | 2014-02-21 | |
US61/942,941 | 2014-02-21 | ||
US201461974816P | 2014-04-03 | 2014-04-03 | |
US201461974725P | 2014-04-03 | 2014-04-03 | |
US201461974785P | 2014-04-03 | 2014-04-03 | |
US61/974,725 | 2014-04-03 | ||
US61/974,816 | 2014-04-03 | ||
US61/974,785 | 2014-04-03 | ||
PCT/US2014/065742 WO2015077154A1 (en) | 2013-11-20 | 2014-11-14 | Treatment of homozygous familial hypercholesterolemia |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017505285A JP2017505285A (ja) | 2017-02-16 |
JP2017505285A5 true JP2017505285A5 (US07585860-20090908-C00112.png) | 2017-12-21 |
Family
ID=52014370
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016532631A Withdrawn JP2017505285A (ja) | 2013-11-20 | 2014-11-14 | ホモ接合性家族性高コレステロール血症の治療 |
Country Status (14)
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
US9624172B2 (en) | 2014-02-17 | 2017-04-18 | Hetero Research Foundation | Polymorphs of lomitapide and its salts |
US10272058B2 (en) | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
UA120756C2 (uk) | 2014-03-20 | 2020-02-10 | Сімабей Терапьютікс, Інк. | Лікування внутрішньопечінкових холестатичних захворювань |
DK3129018T3 (da) | 2014-04-11 | 2020-01-20 | Cymabay Therapeutics Inc | Behandling af NAFLD og NASH |
BR102015025502B1 (pt) * | 2015-04-30 | 2022-06-21 | Aegerion Pharmaceuticals, Inc | Composição de lomitapida, tablete, produto de lomitapida, métodos para analisar uma composição de amostra de lomitapida e para determinar uma quantidade de uma impureza em uma amostra da composição |
CA2996701C (en) * | 2015-08-25 | 2024-05-28 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder |
CN105481758A (zh) * | 2016-01-13 | 2016-04-13 | 天津药物研究院有限公司 | 一种洛美他派晶型ⅰ及其制备方法和用途 |
KR20190003679A (ko) * | 2016-04-28 | 2019-01-09 | 리제너론 파아마슈티컬스, 인크. | 가족성 고콜레스테롤혈증을 지닌 환자를 치료하는 방법 |
WO2017200715A1 (en) * | 2016-05-19 | 2017-11-23 | Cymabay Therapeutics, Inc. | Treatment of severe hyperlipidemia |
US10512622B2 (en) | 2017-07-14 | 2019-12-24 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
WO2019101151A1 (zh) * | 2017-11-23 | 2019-05-31 | 浙江海正药业股份有限公司 | 一种海泽麦布和HMG-CoA还原酶抑制剂的药物组合物 |
US20220040332A1 (en) * | 2018-12-20 | 2022-02-10 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating familial hypercholesterolemia |
CA3125765A1 (en) | 2019-01-18 | 2020-07-23 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
US20210145774A1 (en) | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Treatment of alcoholic liver disease |
WO2021097034A1 (en) | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
US5883109A (en) | 1996-07-24 | 1999-03-16 | Bristol-Myers Squibb Company | Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug |
US6066653A (en) | 1997-01-17 | 2000-05-23 | Bristol-Myers Squibb Co. | Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs |
US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
BRPI0414268B8 (pt) | 2003-09-19 | 2021-05-25 | Janssen Pharmaceutica Nv | ácidos 4-((fenoxialquil)tio)-fenoxiacéticos, análogos, e composições farmacêuticas |
WO2005087234A1 (en) | 2004-03-05 | 2005-09-22 | The Trustees Of The University Of Pennsylvania | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
JO3006B1 (ar) | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
ES2712052T3 (es) * | 2008-10-17 | 2019-05-09 | Cymabay Therapeutics Inc | Métodos para reducir partículas de LDL pequeñas y densas |
JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
-
2014
- 2014-11-14 US US14/541,835 patent/US20150139987A1/en not_active Abandoned
- 2014-11-14 AU AU2014353246A patent/AU2014353246A1/en not_active Abandoned
- 2014-11-14 EA EA201691039A patent/EA201691039A1/ru unknown
- 2014-11-14 MX MX2016006583A patent/MX2016006583A/es unknown
- 2014-11-14 WO PCT/US2014/065742 patent/WO2015077154A1/en active Application Filing
- 2014-11-14 CN CN201480063803.XA patent/CN105764498A/zh active Pending
- 2014-11-14 EP EP14809184.6A patent/EP3071198A1/en not_active Withdrawn
- 2014-11-14 CA CA2930069A patent/CA2930069A1/en not_active Abandoned
- 2014-11-14 KR KR1020167016225A patent/KR20160079124A/ko not_active Application Discontinuation
- 2014-11-14 JP JP2016532631A patent/JP2017505285A/ja not_active Withdrawn
-
2016
- 2016-05-12 PH PH12016500886A patent/PH12016500886A1/en unknown
- 2016-05-19 IL IL245748A patent/IL245748A0/en unknown
- 2016-05-20 CL CL2016001215A patent/CL2016001215A1/es unknown
- 2016-10-28 HK HK16112450.0A patent/HK1224186A1/zh unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2017505285A5 (US07585860-20090908-C00112.png) | ||
JP2017513836A5 (US07585860-20090908-C00112.png) | ||
HRP20192299T1 (hr) | Liječenje nafld i nash | |
JP2017508817A5 (US07585860-20090908-C00112.png) | ||
CY1119575T1 (el) | Ενωσεις υποκατεστημενης βενζαλδεϋδης και μεθοδοι για τη χρηση τους στην αυξηση της οξυγονωσης του ιστου | |
CY1120939T1 (el) | Συνδυασμος ρεγοραφενιμπης και ακετυλοσαλικυλικου οξεος για τη θεραπευτικη αντιμετωπιση του ορθοκολικου καρκινου | |
AR122580A2 (es) | Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales | |
RS54873B1 (sr) | Policiklična-karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba | |
JP2014221779A5 (US07585860-20090908-C00112.png) | ||
JP2015078230A5 (US07585860-20090908-C00112.png) | ||
JP2014218522A5 (US07585860-20090908-C00112.png) | ||
JP2016513717A5 (US07585860-20090908-C00112.png) | ||
JP2014521735A5 (US07585860-20090908-C00112.png) | ||
PH12016500886A1 (en) | Treatment of homozygous familial hypercholesterolemia | |
JP2014507446A5 (US07585860-20090908-C00112.png) | ||
UA109698C2 (xx) | Похідні азаіндазолу або діазаіндазолу як медикамент | |
CY1121910T1 (el) | Φαρμακευτικο παρασκευασμα που περιεχει παραγωγο διυδροκιναζολινης με αντιϊικη δραση | |
JP2016510326A5 (US07585860-20090908-C00112.png) | ||
EA201490552A1 (ru) | Холиновая соль замещенного циклобутендиона, обладающая противовоспалительной способностью | |
MX2017002967A (es) | Composicion farmaceutica novedosa que contiene derivado de acido hidroxamico o sal del mismo. | |
EP3412668A3 (en) | A selective inhibitor of phosphatidylinositol 3-kinase-gamma | |
NZ605444A (en) | Salt and solvates of a tetrahydroisoquinoline derivative | |
NZ602029A (en) | Use of meloxicam for the long-term treatment of kidney disorders in cats | |
AR095098A1 (es) | Derivado de azol benceno con actividad inhibidora de xantina oxidasa | |
JP2015516419A5 (US07585860-20090908-C00112.png) |